Abiopharma

🔍 RA CAPITAL MANAGEMENT, L.P. (Executive)

Company: Mineralys Therapeutics, Inc. (MLYS)

Report Date: 2025-09-04

Detailed Transactions and Holdings:

• Acquired 1,176,470 shares of Common Stock at $25.5 per share (Direct)
  Date: 2025-09-04 | Code: P | equity_swap_involved: 0 | shares_owned_after: 5,456,521.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-09-04 | Code: H | nature_of_ownership: See footnotes | shares_owned_after: 1,867,229.00 | Footnotes: F2

Footnotes:

• F1: Held directly by the RA Capital Healthcare Fund, L.P. (the "Fund").
• F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
• F3: Held directly by Nexus Fund III.
• REMARKS: Dr. Derek DiRocco, a Partner of the Adviser, serves on the Issuer's board of directors.